Welcome to our dedicated page for CERo Therapeutics news (Ticker: CERO), a resource for investors and traders seeking the latest updates and insights on CERo Therapeutics stock.
CERo Therapeutics Holdings, Inc. (CERO) is a biotechnology company developing engineered T cell immunotherapies for cancer, with a focus on its CER-T (Chimeric Engulfment Receptor T cell) platform and lead candidate CER-1236. The CERO news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how this clinical-stage program is progressing.
News about CERo frequently centers on clinical trial milestones for CER-1236, including updates from the ongoing first-in-human, multi-center, open-label Phase 1/1b trial known as CertainT-1. Articles describe cohort initiations, completion of dose-limiting toxicity observation periods, dose escalation decisions, and early safety and pharmacokinetic observations in patients with acute myeloid leukemia and related bone marrow diseases such as myelodysplastic syndrome and myelofibrosis.
Investors and observers can also expect regulatory and scientific conference updates, such as announcements of data presentations at meetings like the Society for Immunotherapy of Cancer, where CERo has highlighted preclinical data on sustained cell expansion and cytokine responses for CER-1236. These items provide context on how the company’s CER-T platform is being evaluated by the scientific and medical community.
Another recurring theme in CERO news is capital markets and listing status. The company has issued releases about its transition from Nasdaq to OTC Markets, including listings on OTC PINK and OTCQB, and about financing arrangements involving convertible preferred stock and equity purchase agreements. These updates outline how CERo is seeking to fund its research and maintain access to public markets.
By reviewing the CERO news page, readers can track clinical development steps, financing transactions, listing developments, and corporate communications that shape the outlook for CERo’s engineered T cell immunotherapy programs over time.
CERo Therapeutics (OTCQB: CERO) provided a shareholder update on March 11, 2026 describing clinical, financing, governance, and strategic progress. Key points: early clinical activity for lead candidate CER-1236 (20–70x cell expansion; one MDS patient with >56-day platelet transfusion independence), convertible debt funding to sustain operations, engagement of an investment bank to pursue a Nasdaq relisting, and the appointment of Eric Francois to the board.
CERo Therapeutics (OTCQB: CERO) appointed industry veteran Eric Francois to its Board of Directors effective Feb 17, 2026. Francois brings over 25 years in life sciences finance, including 18 years as a senior banker and prior service as CFO who helped raise over $300M.
The company highlighted his strengths in capital raising, M&A and business development to support CERo's cellular immunotherapy programs and ongoing human clinical trial.
CERo Therapeutics (OTCQB:CERO) will present interim Phase 1 CERTAIN-T data at ASTCT/CIBMTR on February 5, 2026. Key findings include approximately 20–70-fold in vivo cell expansion peaking days 7–14, no dose-limiting toxicities in first four patients, and an index AML/MDS patient achieving platelet transfusion independence >56 days. The trial has been amended to include transfusion-dependent MDS, high-risk MDS, and post-JAK-inhibitor myelofibrosis; cohort 2 enrollment is underway.
CERo Therapeutics (OTCQB: CERO) provided a Phase 1 CertainT-1 clinical update for CER-1236 in AML on January 7, 2026.
Key points: investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events to date; a patient with MDS that progressed to AML had a 61-day platelet transfusion–free interval, exceeding an 8-week benchmark; transfusion independence ended after a later round of lymphodepleting chemotherapy plus CER-1236. The company filed an amendment with the FDA to add advanced MDS and myelofibrosis cohorts and will host an analyst call on Jan 7, 2026 at 5:00 PM ET.
CERo Therapeutics (OTCQB: CERO) provided a Phase 1 CertainT-1 clinical update for CER-1236 in acute myeloid leukemia (AML) on December 17, 2025. The company reported completion of the dose‑limiting toxicity (DLT) observation period for Cohort 1.
The first patient in Cohort 2 was dosed at 4e6 cells/kg (four times the Cohort 1 dose of 1e6 cells/kg) and completed the DLT observation period. A second patient in Cohort 1 received a fourth additional dose and remains on study. The trial is a first‑in‑human, multi‑center, open‑label Phase 1/1b study evaluating safety and preliminary efficacy with primary endpoints including AEs, SAEs, DLTs, ORR, CR, cCR, and MRD; PK is a secondary measure.
CERo Therapeutics (OTCQB: CERO) announced its shares will begin trading on the OTCQB market under ticker CERO effective December 2, 2025 at 8:00 AM ET.
No investor action is required. The company said it is evaluating additional up‑list options, including a potential listing on a major exchange to improve liquidity and investor accessibility. Management reiterated focus on advancing its Phase 1 trial of CER‑1236 for AML, noting the starting dosage in the current cohort was increased significantly versus the prior cohort.
CERo Therapeutics (OTC PINK: CERO) initiated the second cohort of its first-in-human Phase 1/1b trial of CER-1236 in acute myeloid leukemia on Nov 5, 2025. The first patient in cohort 2 received an initial dose equal to twice the cohort‑1 starting dose and a second identical dose 48 hours later. Investigators reported no dose‑limiting toxicities to date, supporting escalation. The open‑label, multi‑center study uses dose escalation to find a Phase 2 dose and an expansion phase to assess safety and preliminary efficacy with endpoints including AEs/SAEs, DLTs, ORR, CR, cCR, MRD and PK.
The company noted observed cell expansion and continues dosing while evaluating options to list the stock on a public exchange.
CERo Therapeutics (OTC PINK: CERO) will present preclinical data for lead compound CER-1236 in a poster at the Society for Immunotherapy of Cancer (SITC) conference, Nov 5–9, 2025, with the poster scheduled for Nov 8, 2025.
The poster, titled “CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion,” reports preclinical findings of sustained cell expansion across multiple antigen stimulations and a robust cytokine response, compared with CD3/CD28 polyclonal stimulation which induced strong initial activation but led to exhaustion.
The company noted these data align broadly with observations from its ongoing Phase 1/1b first-in-human study in AML/MDS populations; the trial is a two-part dose-escalation and expansion study assessing safety, tolerability, ORR/CR/cCR and MRD, with PK as a secondary measure.
CERo Therapeutics (OTC: CERO) confirmed its shares continue trading under the OTC PINK market, effective at market open on October 31, 2025, with no action required from investors.
The company said it is evaluating up-list options to improve liquidity and accessibility while maintaining full operations and staffing. CERo highlighted progress in its Phase 1 AML program for CER-1236, announcing initiation of Cohort 2 and an FDA-approved significant dosage increase for that cohort.
CERo Therapeutics (Nasdaq: CERO) announced that a Nasdaq Hearings Panel denied its request to continue listing, and Nasdaq trading will be suspended at the open on October 31, 2025. The Panel found the company noncompliant with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders’ equity, retroactive to April 22, 2025. The company previously reported regaining compliance after financings and asset transactions but later recorded a discounted sale of $5.0M marketable securities that prompted Nasdaq staff’s re‑determination.
CERo said it has received ~$2.25M from a Series E closing and subscriptions for ~$4.75M tied to conditions, is pursuing review by the Nasdaq Council, plans to seek trading on the OTC Markets, and intends to continue clinical trials including dosing of CER-1236, which showed early cell expansion and no observed toxicity in initial AML patients.